Alnylam Pharmaceuticals Inc to Discuss FDA Approval of OXLUMO (Lumasiran) Conference Call Summary - Thomson StreetEvents

Alnylam Pharmaceuticals Inc to Discuss FDA Approval of OXLUMO (Lumasiran) Conference Call Summary

Alnylam Pharmaceuticals Inc to Discuss FDA Approval of OXLUMO (Lumasiran) Conference Call Summary - Thomson StreetEvents
Alnylam Pharmaceuticals Inc to Discuss FDA Approval of OXLUMO (Lumasiran) Conference Call Summary
Published Nov 24, 2020
21 pages (10668 words) — Published Nov 24, 2020
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of ALNY.OQ conference call or presentation 24-Nov-20 1:00pm GMT

  
Brief Excerpt:

...A. OXLUMO: On 11/23/20 FDA approved OXLUMO for treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. 1....

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Alnylam Pharmaceuticals Inc
Ticker
ALNY.OQ
Time
1:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : I'll add my congrats as well. It's definitely a great achievement for the team.

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : So I want to ask about the difference between payer discussion in the U.S. and in Europe. I understand the price and the VBA discussion framework is primarily in the U.S. How about the payer dynamic in Europe?

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Yes.

Table Of Contents

Alnylam Pharmaceuticals Inc to Discuss Topline HELIOS-A Phase 3 Results of Vutrisiran - Conference Call Summary – 2021-01-07 – US$ 54.00 – Edited Brief of ALNY.OQ conference call or presentation 7-Jan-21 1:00pm GMT

Alnylam Pharmaceuticals Inc R&D Day 2020 (Event 2) Transcript – 2020-12-16 – US$ 54.00 – Edited Transcript of ALNY.OQ corporate analyst meeting</ 16-Dec-20 2:00pm GMT

Alnylam Pharmaceuticals Inc R&D Day 2020 (Event 1) Transcript – 2020-12-15 – US$ 54.00 – Edited Transcript of ALNY.OQ corporate analyst meeting</ 15-Dec-20 2:00pm GMT

Alnylam Pharmaceuticals Inc at Nasdaq Virtual Investor Conference Transcript – 2020-12-04 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 4-Dec-20 4:00pm GMT

Alnylam Pharmaceuticals Inc to Discuss FDA Approval of OXLUMO (Lumasiran) Conference Call Transcript – 2020-11-24 – US$ 54.00 – Edited Transcript of ALNY.OQ conference call or presentation 24-Nov-20 1:00pm GMT

Alnylam Pharmaceuticals Inc at Stifel Virtual Healthcare Conference Transcript – 2020-11-16 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 16-Nov-20 7:00pm GMT

Alnylam Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript – 2020-11-09 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 9-Nov-20 5:30pm GMT

Alnylam Pharmaceuticals Inc Q3 2020 Earnings Call Summary – 2020-11-05 – US$ 54.00 – Edited Brief of ALNY.OQ earnings conference call or presentation 5-Nov-20 1:30pm GMT

Alnylam Pharmaceuticals Inc Q3 2020 Earnings Call Transcript – 2020-11-05 – US$ 54.00 – Edited Transcript of ALNY.OQ earnings conference call or presentation 5-Nov-20 1:30pm GMT

Alnylam Pharmaceuticals Inc at H C Wainwright Hepatitis B Virus (HBV) Mini-Conference (Virtual) Transcript – 2020-10-20 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 20-Oct-20 4:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Alnylam Pharmaceuticals Inc to Discuss FDA Approval of OXLUMO (Lumasiran) Conference Call Summary" Nov 24, 2020. Alacra Store. May 02, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Alnylam-Pharmaceuticals-Inc-to-Discuss-FDA-Approval-of-OXLUMO-Lumasiran-Conference-Call-B13521601>
  
APA:
Thomson StreetEvents. (2020). Alnylam Pharmaceuticals Inc to Discuss FDA Approval of OXLUMO (Lumasiran) Conference Call Summary Nov 24, 2020. New York, NY: Alacra Store. Retrieved May 02, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Alnylam-Pharmaceuticals-Inc-to-Discuss-FDA-Approval-of-OXLUMO-Lumasiran-Conference-Call-B13521601>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.